Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Retrieved on:
Tuesday, February 15, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, NASDAQ, NYSE, OPKO Health, Patient, Quality of life, Perception, Region, Puberty, Injection, Union, Transgender hormone therapy, Safety, Standard of care, Pfizer, Growth hormone, PFE, European Commission, Disease, Disease management, Pituitary gland, Growth, Multimedia, Â, Royal commission, Caregiver, Face, GHD, Birth control, Pharmaceutical industry, Inc., EU, the NGENLATM (somatrogon) Injection Studies, NGENLATM (somatrogon) Injection, GENOTROPIN® (somatropin), Pfizer: Breakthroughs That Change Patients’ Lives, OPKO Health, Inc., THE NGENLATM (SOMATROGON) INJECTION STUDIES, NGENLATM (SOMATROGON) INJECTION, GENOTROPIN® (SOMATROPIN), PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, OPKO HEALTH, INC.
We are pleased that the marketing authorization in the European Union will enable more children with growth hormone deficiency to benefit from once-weekly treatment.
Key Points:
- We are pleased that the marketing authorization in the European Union will enable more children with growth hormone deficiency to benefit from once-weekly treatment.
- The marketing authorization of NGENLA is valid in all EU Member States as well as Iceland, Norway and Liechtenstein.
- In this study, 224 prepubertal, treatment-nave children with growth hormone deficiency (GHD) were randomized 1:1 to receive NGENLA once-weekly or GENOTROPIN (somatropin) once-daily.
- NGENLA (somatrogon) is a synthetic growth hormone that works by replacing the lack of growth hormone in the body.